PolyActiva Announces Positive Phase IIa Trial Results in Low

– Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically – Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma...

Related Keywords

Australia , Melbourne , Victoria , Canada , Toronto , Ontario , San Francisco , California , United States , Australian , Like Ahmed , Russell Tait , Michael Coote , Polyactiva Pty Ltd , Prezia Technology , Drug Delivery Technology , University Of Utah , Horizons Forum , University Of Toronto , Prezia Sustained Drug Delivery Technology , Prism Eye Institute In Ontario , Secondary Efficacy Endpoints Met , Significant Reduction , Intra Ocular Pressure , Ocular Implant , Primary Open Angle Glaucoma , Chief Executive Officer , Annual Glaucoma , Associate Professor Michael Coote , Melbourne Eye Specialists , Prism Eye Institute , Assistant Professor , Clinical Professor , Sustained Drug Delivery Technology ,